CN3 ONCOLOGISTS' COST-EFFECTIVENESS THRESHOLDS FOR NEW CANCERTHERAPIES

The additional mean cost of pemetrexed plus cisplatin therapy, over cisplatin monotherapy, was A$14,032.78 per patient. The mean and median survival gain with pemetrexed plus cisplatin therapy was found to be 0.191 and 0.233 years, respectively, relative to cisplatin monotherapy, over the 27-month period of observation. The cost per life-year saved was A$73,470.04 for mean and A$60,226.52 for median incremental survival. CONCLUSION: This survival benefit is a highly patient-relevant outcome. This economic evaluation found that pemetrexed plus cisplatin therapy offers an acceptable cost-effectiveness ratio for a small population of MPM patients in Australia.